OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.75
−0.04%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$13.77
From 52W high−0.43%
Volume3.25M
Market cap$3.61B
P/E (TTM)17.4x
P/S (TTM)0.6x
Div yield0.58%
Key dataOct 19, 2026
Open
$13.77
From 52W high
−0.43%
Volume
3.25M
Market cap
$3.61B
ValuationView details →
P/E (Fwd)
3.9x
EV/EBITDA
8.4x
P/E (TTM)
17.4x
RSI (14)
51.4
MomentumView details →
1D Return
−0.04%
YTD Return
+91.63%
SummaryUpdated Jun 1, 2026
Organon & Co. (NYSE:OGN) is a global healthcare company that was spun off from Merck & Co. in 2021, focusing on women's health, biosimilars, and established pharmaceutical brands. Founded as an independent entity in 2020 and incorporated in Jersey City, New Jersey, the company went public in May 2021. Organon operates as a specialty pharmaceutical company with a diverse portfolio of prescription therapies sold in the United States and internationally, serving healthcare providers, patients, and health systems worldwide.
Similar companies
Latest newsMore news →
Organon & Co. said it plans to release its third-quarter 2026 financial results through its regularly scheduled Form 10-Q filing and disclose non-GAAP measures with reconciliations to comparable GAAP measures.12h agoOrganon announced it will present new real-world analyses of VTAMA (tapinarof) cream, 1% for eczema patients at the 2026 Fall Clinical Dermatology Conference.18d agoOrganon & Co. reported quarterly earnings on April 30th, with EPS of $0.71 missing consensus of $0.83 and revenue of $1.46 billion missing consensus of $1.49 billion.110d ago